Top Markets
Coin of the day
Aroa Biosurgery Limited Aroa Biosurgery Limited

Aroa Biosurgery Limited

ARX
Rangering i aksjer #20200
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated... Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
Aksjekurs
$0.39848591
Markedsverdi
$137.67M
Endring (1 dag)
-1.74%
Endring (1 år)
-3.96%
Land
NZ
Handel Aroa Biosurgery Limited (ARX)

Kategori

Inntekter for Aroa Biosurgery Limited (ARX)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Aroa Biosurgery Limited er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Aroa Biosurgery Limited fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
- -
DE